In this article, we will take a look at the Best Get Rich Fast Stocks to Buy Right Now.
In today’s fast-paced world, everyone is prioritising investments that have both high and relatively quick returns. The idea of getting “rich fast” is often met with skepticism, and for good reason, as many believe that sustainable wealth is built over time. However, sometimes markets present opportunities that, if seized, can translate into outsized returns in a short period. Such opportunities can be assessed through careful stock selection based on fundamentals, valuation, and upside potential.
While market discussions currently revolve around valuation concerns, some market participants still see drivers of healthy performance in 2026. According to a publication by JPMorgan, titled “2026 market outlook: A multidimensional polarization” and posted on December 09, 2025, the upcoming year will be shaped by the acceleration of AI, uneven monetary policy, and increasing market polarization. These, together with the continuously changing U.S. policy agenda, will define the global macro and market space. For 2026, the writer was bullish on global equities, anticipating double-digit returns across both developed markets (DM) and emerging markets (EM).
In the report, Dubravko Lakos-Bujas, Head of Global Markets Strategy, JPMorgan, stated:
“The AI-driven supercycle is fueling record capex and rapid earnings expansion. This momentum is spreading geographically and across a diverse list of industries, from technology and utilities to banks, healthcare and logistics, creating winners and losers in the process.”
With this outlook in mind, we have compiled a list of best get rich fast stocks to buy right now. These stocks primarily belong to the healthcare and technology sectors.
Source: Pexels
Our Methodology
For this article, we considered stocks with a market capitalization between 300 million and 2 billion. Next, we filtered for stocks with a 5-year beta between 1.5 and 3 and an average daily volume over the last 20 trading days of over 1 million. We then shortlisted the thirteen companies with the highest upside potential and ranked them in ascending order. We also included data on hedge fund holdings in these companies based on Insider Monkey’s database, as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
13. Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
Upside Potential as of December 24, 2025: 79.92%
Number of Hedge Fund Holders: 21
Share Price as of December 24, 2025: $10.56
As of December 24, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a consensus buy from all eleven analysts covering the stock. While the target price ranges from $12 to $30, the median price target of $19 translates to an upside potential of 79.92%.
On December 18, Raymond James initiated coverage on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a ‘Strong Buy’ rating and a price target of $25, citing solid results from two Phase 1/2 clinical trials and encouraging feedback from the FDA. With that said, the company’s lead candidate, LX2006, an AAV gene therapy for cardiomyopathy associated with Friedreich’s Ataxia, is “well-positioned for success” in its pivotal trial, the analyst asserted.
Raymond James expects the stock to gain momentum in 2026 following a finalized pivotal protocol with the FDA and initial proof of concept data on LX2020, an unmodeled gene therapy asset. The firm anticipates LX2006 revenue of $14.1 million in FY27, going as high as $805.3 million in FY32.
Earlier on December 10, Cantor Fitzgerald reaffirmed an ‘Overweight’ rating on Lexeo Therapeutics, Inc. (NASDAQ:LXEO), with a price target of $19. The reaffirmation, implying an upside potential of around 80%, is driven by the prospects of the company’s PKP2-ACM program. The analyst highlighted that the market remains focused on Lexeo’s Friedreich’s ataxia program and the PKP2-ACM program appears “under the radar,” particularly as the upcoming data expected in the next month could shift market perception.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a New York-based clinical-stage genetic medicine company. Founded in 2017, the company has a pipeline of programs, including LX2006, LX2020, and LX2021.
12. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)
Upside Potential as of December 24, 2025: 82.43%
Number of Hedge Fund Holders: 29
Share Price as of December 24, 2025: $13.43
According to TheFly, JonesResearch initiated coverage on Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) with a ‘Buy’ rating and set a price target of $61 on December 23, signaling an upside potential of 354.21% from the current price.
While anticipating “strong” clinical data from initial stages leading to positive Phase 3 results for lead asset MM120 in generalized anxiety disorder (GAD) and major depressive disorder (MDD), the firm believes Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is well-positioned to benefit from ongoing trends that prioritize the development of psychedelic agents in psychiatry.
Although there are clinical and regulatory risks associated with its lead candidate due to the relation to LSD, the robust Phase III data will potentially result in regulatory approval, the firm concluded.
A day earlier, Patrick Trucchio, an analyst at H.C. Wainwright, reaffirmed a ‘Buy’ rating on Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), with an unchanged price target of $55. This translates to an upside potential of about 310%.
Overall, Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a consensus buy among all thirteen analysts covering the stock, as of December 24. With a median price target of $24.50, the stock exhibits an upside potential of 82.43%.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a New York-based clinical-stage biopharmaceutical company specializing in novel treatments for brain health disorders. The company is dedicated to transforming how unmet needs like Anxiety Disorders and Depression are satisfied.
11. Tilray Brands, Inc. (NASDAQ:TLRY)
Upside Potential as of December 24, 2025: 88.49%
Number of Hedge Fund Holders: 13
Share Price as of December 24, 2025: $10.08
As of December 24, Tilray Brands, Inc. (NASDAQ:TLRY) has mixed analyst sentiment, with slightly more than 60% of analysts covering the stock assigning a Hold rating and the remaining 36% recommending buying the stock. While the target price ranges from $8.50 to $25, the median price target of $19 reflects an upside potential of 88.49%.
On December 22, Nadine Sarwat, an analyst at Bernstein, reiterated a ‘Market Perform’ rating on Tilray Brands, Inc. (NASDAQ:TLRY), while substantially raising the price target to $10 from $1.
The firm highlighted President Trump’s cannabis- related Executive Order that has two aims: directing the Attorney General to take all the necessary steps to reschedule cannabis from Schedule I to III, and instructing his Administration to work with Congress to revise the statutory definition of hemp-derived cannabinoid product to incorporate many full-spectrum CBD products. This would also involve establishing a regulatory approach for these offerings and accelerating research.
Bernstein pointed out that cannabis has largely emerged as a bipartisan issue, with Gallup revealing that 64% of Americans are in favour of cannabis legalization in 2025. Despite it being a meaningful figure, it still represents a drop from the 70% peak reported in 2023.
Tilray Brands, Inc. (NASDAQ:TLRY) is a Canadian lifestyle consumer products company specializing in medical cannabis products. Incepted in 2018, the company operates through four segments: Beverage, Cannabis, Distribution, and Wellness.
10. Domo, Inc. (NASDAQ:DOMO)
Upside Potential as of December 24, 2025: 91.66%
Number of Hedge Fund Holders: 20
Share Price as of December 24, 2025: $8.87
On December 24, Tom Blakey from Cantor Fitzgerald assumed coverage on Domo, Inc. (NASDAQ:DOMO) with an ‘Overweight’ rating and a price target of $22, according to TheFly. This reaffirmation follows the firm’s revised research coverage for the Security & Infrastructure Software sector, following the analyst departure and resource reallocation.
Earlier, on December 8, an analyst at Stephens said that Domo, Inc. (NASDAQ:DOMO) could be a takeover target for Snowflake or Databricks. He noted this after raising the price target on Confluent Inc. (NASDAQ:CFLT) and downgrading it from Overweight to Equal Weight. TheFly reports that the update came after IBM committed to paying $31 per share for Confluent in its takeover. The firm believes the agreement highlights the importance of real-time streaming workloads for artificial intelligence and legacy database migration and that this “could portend a larger trend of best-in-class data technologies combining with firms that have larger distribution and complementary products.”
On the other hand, DA Davidson trimmed the price target on Domo, Inc. (NASDAQ:DOMO) to $10.00 from $13.00, keeping a Neutral rating, on December 5. Two days earlier, the company delivered its third-quarter fiscal 2026 results, reporting revenue in line with consensus estimates but billings short of consensus due to prolonged sales cycles for partner deals. The firm noted that it is “waiting to see more consistent execution and upside to the growth outlook before becoming more constructive.”
Domo, Inc. (NASDAQ:DOMO) is a Utah-based company operating a cloud-based modern AI and data products platform. Incorporated in 2010, the company has a strategic collaboration with Altis Consulting to offer transformative data solutions.
9. COMPASS Pathways plc (NASDAQ:CMPS)
Upside Potential as of December 24, 2025: 119.14%
Number of Hedge Fund Holders: 27
Share Price as of December 24, 2025: $6.84
As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of the analysts covering the stock. With a target price range of $8 to $40, the median price target of $15 translates to an upside potential of 119.14% from the current price.
On December 17, Gavin Clark-Gartner, an analyst at Evercore ISI, reaffirmed a ‘Hold’ rating on COMPASS Pathways plc (NASDAQ:CMPS), keeping a price target of $8. This reflects an upside potential of 16.87% from the current level.
Earlier, on December 9, Oppenheimer upgraded COMPASS Pathways plc (NASDAQ:CMPS) to Outperform from Perform, with a price target of $15. This revision is driven by the prospects of the company’s psilocybin therapy for treatment-resistant depression. The firm believes that the company’s psilocybin-based therapy, COMP360, is well-positioned to lead the transformation of psychedelic medicine in neuropsychiatry.
Oppenheimer sees a record sales opportunity of nearly $1.5 billion for the treatment, which appears substantial considering the company’s current market capitalization of over $600 million. The research firm also noted that COMPASS Pathways plc (NASDAQ:CMPS) is poised to advance beyond key upcoming catalysts, given its strong financial footing with an adequate cash runway, and expects it to benefit from an early-mover advantage in the psychedelics space.
COMPASS Pathways plc (NASDAQ:CMPS) is a London-based biotechnology company emphasizing mental health. Founded in 2020, the company is committed to mental well-being.
8. Cerus Corporation (NASDAQ:CERS)
Upside Potential as of December 24, 2025: 142.72%
Number of Hedge Fund Holders: 15
Share Price as of December 24, 2025: $2.06
On December 23, TheFly reported that TD Cowen views Cerus Corporation (NASDAQ:CERS)’s Intercept Fibrinogen Complex franchise as an “underappreciated” growth engine in the long haul. The firm believes the newly announced BCA partnership will significantly enhance its adoption, scalability, and profitability across the U.S. blood center space.
With that said, the financial services firm remains confident in the sustainability of the company’s double-digit revenue growth trajectory and finds the current valuation appealing. TD Cowen maintains a ‘Buy’ rating on Cerus Corporation (NASDAQ:CERS) with a price target of $5. This reflects a potential upside of 143%.
Earlier on December 10, Cerus Corporation (NASDAQ:CERS) announced that it had signed a purchasing agreement with Blood Centers of America (BCA), a leading blood supply cooperative in the United States. The agreement incorporates the company’s complete INTERCEPT product offering, including the pathogen reduction technology.
With an aim to enhance awareness and adoption of pathogen reduction technologies, the venture is anticipated to “provide access to pathogen-reduced platelets for new customers.” As stated by the COO of Cerus Corporation (NASDAQ:CERS), Vivek Jayaraman,
“I believe this agreement has the potential to be quite positive for BCA, their blood center membership and Cerus.”
Cerus Corporation (NASDAQ:CERS) is a California-based biomedical products company specializing in the INTERCEPT Blood System. Incorporated in 1991, the company offers platelet and plasma systems through a direct sales force and distributors.
7. Absci Corporation (NASDAQ:ABSI)
Upside Potential as of December 24, 2025: 150.70%
Number of Hedge Fund Holders: 18
Share Price as of December 24, 2025: $3.59
As of December 24, Absci Corporation (NASDAQ:ABSI) is a consensus buy among all nine analysts covering the stock. The median price target of $9 translates to an upside potential of 150.70%.
On December 17, H.C. Wainwright reaffirmed the ‘Buy’ rating on Absci Corporation (NASDAQ:ABSI), while raising the price target to $8 from $7. The price target revision, reflecting an upside potential of 125%, follows the firm’s incorporation of ABS-201 into the company’s model. This comes after the company’s investor event in which it discussed the androgenetic alopecia program for ABS-201.
According to the research note, ABS-201 exhibits the potential to expand the proportion of hair follicles in the growth phase relative to the resting phase, a stage during which hair shedding occurs. H.C. Wainwright’s confidence in the ABS-201 program is driven by the strength of the preclinical evidence.
Earlier, on December 11, Absci Corporation (NASDAQ:ABSI) disclosed new preclinical data for its AI-designed antibody, ABS-201, indicating that the drug may effectively stimulate hair growth in human scalp tissue samples. Presented during a Key Opinion Leader seminar, the data showed that ABS-201 targets the prolactin receptor (PRLR) to stimulate hair growth by supporting not only stem cell preservation but also prolonging the active growth phase of hair follicles.
Absci Corporation (NASDAQ:ABSI) is a Washington-based, data-first, generative AI drug-creation company. Founded in 2011, the company integrates AI with scalable wet lab technologies to develop unique antibody therapeutics.
6. ProKidney Corp. (NASDAQ:PROK)
Upside Potential as of December 24, 2025: 152.92%
Number of Hedge Fund Holders: 9
Share Price as of December 24, 2025: $2.57
As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” rating from slightly more than half of the analysts covering the stock. While the price target ranges from $1 to $12, the median price target of $6.50 reflects an upside potential of 152.92%. Among the analysts bullish on the stock is Joseph Pantginis, an analyst at H.C. Wainwright, who assumed coverage on the company with a ‘Buy’ rating and a $12 price target on December 16, according to TheFly. His price target implies about 367% upside from the current price.
With ProKidney Corp. (NASDAQ:PROK) initiating a fresh approach to “postponing progressive kidney dysfunction,” the analyst believes the company’s lead asset, rilparencel, exhibits the potential to redefine how chronic kidney disease is treated.
H.C. Wainwright highlighted that rilparencel, an investigational autologous cell therapy for patients living with chronic kidney disease and type 2 diabetes, has already demonstrated promising results across several Phase 1 and 2 trials. This includes meaningful advancements in estimated glomerular filtration rate (eGFR) drops, a positive safety profile, and a slowed progression to dialysis.
With that said, the company’s current Phase 3 PROACT 1 trial, which is totally in line with its Phase 2 design, has been awarded FDA approval for using eGFR slope as a surrogate endpoint. Through an accelerated regulatory approval process, this could also back a Biologics License Application (BLA) filing.
ProKidney Corp. (NASDAQ: PROK) is a North Carolina-based clinical-stage biotechnology company that provides a cell therapy platform for treating various chronic kidney diseases. Incorporated in 2015, the company is committed to “transforming the treatment landscape for chronic kidney disease.”
5. Atai Beckley N.V. (NASDAQ:ATAI)
Upside Potential as of December 24, 2025: 186.40%
Number of Hedge Fund Holders: 21
Share Price as of December 24, 2025: $4.19
On December 23, Justin Walsh from JonesTrading initiated coverage on Atai Beckley N.V. (NASDAQ:ATAI) with a ‘Buy’ rating and a price target of $16, according to TheFly. This translates to an upside potential of nearly 282%.
According to the firm, the company’s psychedelic and empathogenic drugs pipeline presents “differentiated opportunities” across large neuropsychiatric indications. Walsh believes Atai Beckley N.V. (NASDAQ:ATAI) will benefit from the ongoing trends supporting the development of drugs in these classes. The short half-lives of the company’s BPL-003 and VLS-01 will “allow their use in treatment-resistant depression (TRD),” after Johnson & Johnson’s SPRAVATO (esketamine) commercial approach.
While acknowledging the broad TRD market’s potential to accommodate multiple successful therapies, JonesTrading noted the strength of the company’s lead compounds, led by SPRAVATO. The analyst remains hopeful about the effectiveness of the company’s third clinical asset, EMP-01, in social anxiety disorder (SAD).
Earlier on December 11, Atai Beckley N.V. (NASDAQ:ATAI) announced the approval of a new patent for EMP-01, an oral R-MDMA solution for social anxiety disorder, by the United States Patent and Trademark Office. As said by Srinivas Rao, the Chief Executive Officer and Co-founder,
“This patent grant reinforces the strength of our science and our long-term commitment to building durable, defensible innovation.”
Atai Beckley N.V. (NASDAQ:ATAI), based in Amstelveen, The Netherlands, is a clinical-stage biopharmaceutical company specializing in treatments for mental health. Founded in 2018, the company is committed to transforming patient outcomes.
4. Janux Therapeutics, Inc. (NASDAQ:JANX)
Upside Potential as of December 24, 2025: 249.41%
Number of Hedge Fund Holders: 32
Share Price as of December 24, 2025: $14.31
As of December 24, Janux Therapeutics, Inc. (NASDAQ:JANX) has a consensus rating of buy or equivalent from the majority of the analysts covering the stock. The gap between the high and consensus low price targets is also wide: the consensus 1-year median price target implies nearly 249% upside, while the high price target implies around 948% upside, and the lowest price target implies a 75% upside.
On December 17, Barclays trimmed the price target on Janux Therapeutics, Inc. (NASDAQ:JANX) to $29 from $48, with an unchanged ‘Overweight’ rating. This revision, implying an upside potential of about 103%, is part of the firm’s 2026 outlook.
Later, on December 23, Janux Therapeutics, Inc. (NASDAQ:JANX) provided an update on its Phase 1 study of JANX008, its EGFR-targeted TRACTr. The study evaluates “safety, pharmacokinetics/pharmacodynamics, and evidence of clinical activity.” JANX008 is targeted at the epidermal growth factor receptor (EGFR) and is being evaluated for the treatment of multiple solid tumors, including colorectal carcinoma, non-small cell lung cancer, and small cell lung cancer.
According to the press release,
“The Phase 1a dose-escalation portion of the study has been completed, and the program has initiated expansion cohorts to enable further evaluation and support continued dose optimization across selected solid tumor settings.”
Janux Therapeutics, Inc. (NASDAQ:JANX) is a California-based clinical-stage biopharmaceutical company developing immunotherapies based on the TRACTr and TRACIr platform technologies. Founded in 2017, the company focuses on treating patients with cancer.
3. Canaan Inc. (NASDAQ:CAN)
Upside Potential as of December 24, 2025: 281.19%
Number of Hedge Fund Holders: 10
Share Price as of December 24, 2025: $0.79
As of December 24, Canaan Inc. (NASDAQ:CAN) has a consensus ‘Buy’ or equivalent rating from 86% of the analysts covering the stock. With the median one-year price target of $3, the stock has an upside potential of 281.19%.
On December 8, BTIG initiated coverage on Canaan Inc. (NASDAQ:CAN) with a ‘Buy’ rating and a price target of $3, according to TheFly. This translates to an upside potential of over 280%. Since 2013, the company has produced ASIC mining rigs and now markets its highly efficient A16 model, while also operating a self-mining fleet across eight global data centers and owning approximately 1,600 BTC, the analyst noted.
Through its vertically integrated strategy, Canaan Inc. (NASDAQ:CAN) remains focused on BTC self-mining expansion, wider rig-manufacturing market share, and power-infrastructure access, BTIG concluded. The company has a dual business model that not only offers mining equipment to third-party operators but also operates its own mining fleet.
In the third quarter of 2025, Canaan Inc. (NASDAQ:CAN) expanded its position in manufacturing by establishing a Bitcoin rig production facility in California, thus enhancing its production capabilities beyond its initial markets. Although the company also holds 4,000 Ethereum, its near-term strategy primarily involves expanding Bitcoin self-mining capacity and growing its share in rig manufacturing.
Canaan Inc. (NASDAQ:CAN) is a Singapore-based company that engages in bitcoin mining machine sales, self-mining operations, and consumer mining products. Incorporated in 2013, the company also assembles and distributes mining equipment and spare parts.
2. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Upside Potential as of December 24, 2025: 307.41%
Number of Hedge Fund Holders: 21
Share Price as of December 24, 2025: $8.10
As of December 24, 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has a ‘Buy’ or equivalent rating from 82% of the analysts covering the stock. While the price target ranges from $17 to $45, the one-year median price target of $33 translates to an upside potential of over 300%.
On December 19, Scott Bizily, the CLO of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), offloaded 1,635 shares of the company’s stock, worth a total of approximately $17,821.
Earlier on December 17, 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) reported positive interim clinical data from its 4D-710 Phase 1 AEROW clinical trial targeting cystic fibrosis lung disease, according to TheFly. Since the previous update, the higher-dose cohorts have demonstrated no new pulmonary or other safety events, with up to 3.5 years of follow-up. 4D-710-related unfavorable events were observed to be mild and resolvable within 2 months in lower-dose cohorts, with no severe 4D-710-related adverse events.
Airway biopsy and brushing outcomes showed stable and dose-dependent CFTR transgene RNA levels at or above physiologically relevant levels compared with non-CF control samples. In the 2.5E14 vg dose cohort, the results were totally in line with the target expression profile, exhibiting evidence of meaningful activity across all endpoints, particularly ppFEV1 and LCI2.5.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a California-based late-stage biotechnology company specializing in adeno-associated virus vectors. Founded in 2013, the company operates through Therapeutic Vector Evolution, a proprietary synthetic vector discovery platform.
1. Autolus Therapeutics plc (NASDAQ:AUTL)
Upside Potential as of December 24, 2025: 495.24%
Number of Hedge Fund Holders: 16
Share Price as of December 24, 2025: 1.68
As of December 24, Autolus Therapeutics plc (NASDAQ:AUTL) is a consensus buy among all eleven analysts covering the stock. With a median price target of $10, the stock boasts an upside potential of 495.24%. Among the analysts positive on the stock is Yanan Zhu, an analyst at Wells Fargo, who reaffirmed a ‘Buy’ rating on the company, setting a price target of $5 on December 8. This translates to an upside potential of around 198%.
On the same day, Autolus Therapeutics plc (NASDAQ:AUTL) delivered preliminary data from its Phase 1 CARLYSLE trial, which demonstrated positive responses in patients suffering from refractory systemic lupus erythematosus (srSLE) targeted by CAR-T cell therapy obecabtagene autoleucel (obe-cel).
During the presentation at the American Society of Hematology Annual Meeting, the study’s data showed that while three patients achieved complete response, five patients achieved DORIS response criteria and exhibited a median onset of 5.1 months. Nine patients were assessable for safety across both the 50 million and 100 million cell dose cohorts.
As stated by Dr. Matthias Will, the Chief Development Officer,
“Data reported from the CARLYSLE trial show an encouraging high rate of DORIS responses and a deep reset in the B cell compartment induced by obe-cel.”
Autolus Therapeutics plc (NASDAQ:AUTL) is a U.K.-based clinical-stage biopharmaceutical company engaging in solutions for cancer and autoimmune diseases. Incorporated in 2014, the company is dedicated to creating “next-generation T-cell immunotherapies for cancer and autoimmune diseases.”
While we acknowledge the potential of AUTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
